Published in Neurotherapeutics on October 01, 2008
Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets (2010) 0.92
Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life. Neurol Sci (2009) 0.84
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci (2007) 2.56
Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol (1981) 2.36
Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med (2003) 2.17
Phenotypic clustering in MPZ mutations. Brain (2004) 1.94
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med (2004) 1.86
CMT1X phenotypes represent loss of GJB1 gene function. Neurology (2007) 1.77
Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology (2008) 1.70
Differentiation of axon-related Schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation. J Cell Biol (1987) 1.67
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology (2005) 1.63
Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. Neurology (2006) 1.59
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain (2005) 1.42
Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol (1997) 1.42
Modulating the expression of disease genes with RNA-based therapy. PLoS Genet (2007) 1.38
Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev (2006) 1.31
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Triple arthrodesis: twenty-five and forty-four-year average follow-up of the same patients. J Bone Joint Surg Am (1999) 1.22
Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord (2007) 1.22
Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol Dis (2005) 1.20
Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol (2007) 1.18
Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet (2007) 1.18
Coexistent hereditary and inflammatory neuropathy. Brain (2003) 1.15
Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol (2007) 1.13
Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet (1998) 1.13
Mechanisms of disease: inherited demyelinating neuropathies--from basic to clinical research. Nat Clin Pract Neurol (2007) 1.12
Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc (1982) 1.12
Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet (2005) 1.11
Morpholino phosphorodiamidate oligonucleotides in zebrafish: a recipe for functional genomics? Brief Funct Genomic Proteomic (2002) 1.10
136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord (2006) 1.05
Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol (2007) 1.01
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res (2006) 0.99
Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Investig Med (2003) 0.98
Pathogenesis of X-linked Charcot-Marie-Tooth disease: differential effects of two mutations in connexin 32. J Neurosci (2003) 0.92
Conducting research in individual patients: lessons learnt from two series of N-of-1 trials. BMC Fam Pract (2006) 0.88
Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet (2001) 0.88
Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease. J Bone Joint Surg Am (1989) 0.88
Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des (2006) 0.87
The dominantly inherited motor and sensory neuropathies: clinical and molecular advances. Muscle Nerve (2006) 0.87
Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis. Mol Cell Neurosci (2005) 0.84
Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J Neurosci Res (2005) 0.83
Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta (1995) 0.83
Therapeutic strategies for the inherited neuropathies. Neuromolecular Med (2006) 0.82
Genetic medicine at the RNA level: modifications of the genetic repertoire for therapeutic purposes by pre-mRNA trans-splicing. C R Biol (2004) 0.81
Night splinting does not increase ankle range of motion in people with Charcot-Marie-Tooth disease: a randomised, cross-over trial. Aust J Physiother (2006) 0.81
Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A: a case series. Am J Hosp Palliat Care (2006) 0.79
Competitive binding of triplex-forming oligonucleotides in the two alternate promoters of the PMP22 gene. Antisense Nucleic Acid Drug Dev (2001) 0.77
Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia. Neurology (1988) 0.77
Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease. Neurology (1986) 0.77
Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database Syst Rev (2007) 0.76